Timing note: Leidos scheduled its 2Q26 results release and conference call for Tuesday, August 4, 2026, at 8:00 a.m. ET—the date is today, not tomorrow. This preview is therefore framed around the key issues investors should assess in the release and call, using information available ahead of the report.
The central question for 2Q is not simply whether Leidos beats or misses near-term expectations. Management explicitly characterized 2Q26 as the expected low point for revenue growth and margins, following some Q1 work pull-forward, the absence of a one-time insurance recovery, and increased investment in strategic growth programs. The more important test is whether management can reaffirm that a softer second quarter is temporary and that growth, bookings, and margins inflect in 3Q–4Q26.
Leidos entered the quarter with a favorable strategic narrative: exposure to defense technology, intelligence/digital infrastructure, cyber, managed health, and energy resilience; a recently closed Entrust acquisition; and a raised full-year outlook. But investors will want proof that these opportunities are converting into awards, revenue, and cash rather than merely expanding the pipeline.
The stock closed at $118.75 on August 3, down roughly 20% from $148.81 on May 4—the session before first-quarter earnings—but up nearly 19% from its June 25 low of $100.00. That performance suggests expectations may be more tempered than immediately following 1Q, while leaving the shares sensitive to the credibility of the second-half recovery message.
After a strong first quarter, Leidos raised FY26 guidance to:
| FY26 metric | Current guidance | Key implication |
|---|---|---|
| Revenue | $18.0B–$18.4B | Includes the contribution from Entrust; management said the organic outlook was otherwise largely unchanged |
| Adjusted EBITDA margin | Mid-13% | Implies margins should recover after the expected 2Q softness |
| Non-GAAP EPS | $12.10–$12.50 | Raised by $0.05 following the Entrust close |
| Operating cash flow | ~$1.8B | Raised by $50M |
The revenue guide equates to an average quarterly run rate of roughly $4.5B–$4.6B, although management has clearly signaled that quarterly performance will not be linear.
Management said in May that Q1 revenue outperformance was partly pulled forward from Q2 and expected a modest Q2 step-down in both revenue run rate and profitability, followed by a more meaningful acceleration in the second half.
For investors, the crucial indicators will be:
A soft 2Q by itself should not undermine the thesis if bookings, funded backlog, program ramps, and guidance support the anticipated second-half progression.
Leidos reported a relatively light 0.8x book-to-bill in 1Q, although trailing-12-month book-to-bill was 1.1x. Total backlog was $48.4B, including $9.6B of funded backlog. Management attributed the weaker quarterly booking figure partly to a slower procurement environment and expected awards to strengthen through the year.
Investors should focus on:
A clear improvement in bookings would make the back-half revenue inflection substantially more believable.
Defense revenue was essentially flat in 1Q, while non-GAAP operating margin fell to 8.3% from 9.8% a year earlier. The pressure reflected a schedule delay on a fixed-price development program. Management argued that the ramp of programs such as integrated air defense and other production-oriented awards should improve profitability as the year progresses.
The key questions are:
This segment is likely the largest upside lever if Leidos can translate its technology pipeline into scaled production revenue without repeating fixed-price execution issues.
Homeland was a major 1Q growth contributor, with revenue up 6%, aided by energy-infrastructure engineering and air-traffic-management demand. However, segment non-GAAP margin declined to 8.5% from 9.4%, reflecting changing customer requirements on a fixed-price program, plus acquisition and joint-venture-related costs at the GAAP level.
The Entrust acquisition is the principal near-term catalyst. Management said it was immediately accretive to FY26 non-GAAP EPS and cash flow, integration was ahead of schedule, and the combined energy-infrastructure opportunity pipeline had expanded to approximately $10B.
Watch for:
The security JV bears watching because, after close, Leidos expects to stop consolidating revenue from that business and instead report its roughly 40% share of JV net income through equity-method income. That will affect reported revenue mix even if the underlying economics are favorable.
Health revenue was flat in 1Q, but the business delivered an exceptional 24.2% non-GAAP operating margin. The debate is whether high Veterans Benefits Administration exam volumes can remain durable as competition and customer procurement evolve.
Management’s position was constructive: exam volumes remained elevated, the VA was working through backlog, and Leidos saw an opportunity to use technology to improve cycle times and preserve a leading role. It also pointed to Military OneSource and the My Service Treatment Record pilot as ways to expand beyond the core exams business.
Investors should look for:
Leidos generated $301M of operating cash flow and $270M of free cash flow in 1Q. It ended the quarter with $6.3B of debt, $457M of cash, and gross leverage of 2.6x, after funding the Entrust acquisition with a mix of cash, commercial paper, and new debt.
The 2Q report should clarify whether Leidos remains on track to produce approximately $1.8B of FY26 operating cash flow while funding higher CapEx, reducing commercial paper, paying its dividend, and repurchasing shares.
Key points to monitor:
The earnings call is likely to hinge on the credibility of the second-half setup. Investors should be prepared for a comparatively muted 2Q operating print because management signaled it in advance. A constructive outcome would pair that softness with maintained FY26 guidance, better bookings, evidence of Defense margin recovery, tangible Entrust traction, and confidence in cash generation.
Conversely, the report becomes more problematic if Leidos attributes weak results to the same timing and execution issues but cannot point to improving awards, funded backlog, or a clear 3Q–4Q ramp.